Notably, SEs also contribute to therapeutic resistance, as seen in multiple myeloma, where SE-driven ITGB7 overexpression fosters cell-adhesion-mediated drug resistance (Chou et al., 2023). Here, ITGB7 is linked to plasma cell myeloma.